Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
243
Views
0
CrossRef citations to date
0
Altmetric
Articles

Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time

Dianne Pultea Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DFKZ), Heidelberg, GermanyCorrespondence[email protected]
View further author information
,
Lina Jansena Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DFKZ), Heidelberg, GermanyView further author information
&
Hermann Brennera Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DFKZ), Heidelberg, Germany;b Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;c German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
Pages 1964-1969 | Received 29 Oct 2021, Accepted 01 Mar 2022, Published online: 27 Mar 2022

References

  • Sweeney MR, Applebaum KM, Arem H, et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol Biomarkers Prev. 2019;28(9):1502–1517.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
  • Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820–829.
  • Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096–1107.
  • Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
  • Fenaux P, Giagounidis A, Selleslag D, for the MDS-004 Lenalidomide del5q Study Group, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1 risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–3776.
  • Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542.
  • De Roos AJ, Deeg HJ, Davis S. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control. 2007;18(10):1199–1208.
  • Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations-Total U.S. (1969-2017) Linked to County Attributes—Total U.S., 1969-2017 Counties, National Cancer Institute, DCPS, Surveillance Research Program, released December 2018.
  • Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Research Data (1973-2016), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2019, based on the November 2018 submission.
  • Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78(9):2004–2010.
  • Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20(3):826–832.
  • Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006; 164(7):689–696.
  • Arias E. United States life tables, 2000. Natl Vit Stat. 2002;1–39.
  • Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Bethesda, MD: National Cancer Institute, 1959.
  • Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307–2316.
  • Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.3.6
  • Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer. 2002;38(5):690–695.
  • Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56.
  • Pulte D, Jansen L, Castro FA, et al. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031–2040.
  • U.S. Food and Drug Administration. Vidaza, Full Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050794s031lbl.pdf.
  • U.S. Food and Drug Administration. Dacogen, Full Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf.
  • U.S. Food and Drug Administration. Revlimid, Full Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021880s041lbl.pdf.
  • U.S. Food and Drug Administration. Gleevec, Full Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf.
  • Zeidan AM, Smith BD, Carraway HE, et al. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br J Haematol. 2017;176(2):241–247.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.